Pharming Group (PHARM) Stock Overview
A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
PHARM Community Fair Values
Create NarrativeSee what 39 others think this stock is worth. Follow their fair value or set your own to get alerts.
Pharming Group N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.22 |
| 52 Week High | €1.41 |
| 52 Week Low | €0.66 |
| Beta | 0.56 |
| 1 Month Change | 0.082% |
| 3 Month Change | 40.59% |
| 1 Year Change | 53.88% |
| 3 Year Change | 22.10% |
| 5 Year Change | 32.98% |
| Change since IPO | -98.71% |
Recent News & Updates
Recent updates
Pharming Group N.V. (AMS:PHARM) Surges 26% Yet Its Low P/S Is No Reason For Excitement
Sep 08
There's No Escaping Pharming Group N.V.'s (AMS:PHARM) Muted Revenues Despite A 29% Share Price Rise
May 10Pharming Group N.V. (AMS:PHARM) Held Back By Insufficient Growth Even After Shares Climb 26%
Dec 21Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price
Feb 14Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?
Nov 11Pharming Group N.V. (AMS:PHARM) Shares Could Be 49% Below Their Intrinsic Value Estimate
Aug 23Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?
Jun 20Is Pharming Group (AMS:PHARM) Using Too Much Debt?
Mar 16Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 41% Above Its Share Price
Feb 17We Think Pharming Group (AMS:PHARM) Can Manage Its Debt With Ease
Dec 08Is Pharming Group (AMS:PHARM) Using Too Much Debt?
Aug 05Pharming Group N.V. Just Missed EPS By 56%: Here's What Analysts Think Will Happen Next
Mar 21These Analysts Think Pharming Group N.V.'s (AMS:PHARM) Sales Are Under Threat
Mar 19Shareholder Returns
| PHARM | NL Biotechs | NL Market | |
|---|---|---|---|
| 7D | -1.6% | -0.9% | -2.0% |
| 1Y | 53.9% | 16.0% | 12.2% |
Return vs Industry: PHARM exceeded the Dutch Biotechs industry which returned 17.8% over the past year.
Return vs Market: PHARM exceeded the Dutch Market which returned 6.9% over the past year.
Price Volatility
| PHARM volatility | |
|---|---|
| PHARM Average Weekly Movement | 8.7% |
| Biotechs Industry Average Movement | 7.3% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in NL Market | 6.0% |
| 10% least volatile stocks in NL Market | 2.2% |
Stable Share Price: PHARM's share price has been volatile over the past 3 months compared to the Dutch market.
Volatility Over Time: PHARM's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Dutch stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 404 | Fabrice Chouraqui | www.pharming.com |
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Pharming Group N.V. Fundamentals Summary
| PHARM fundamental statistics | |
|---|---|
| Market cap | €836.57m |
| Earnings (TTM) | -€7.06m |
| Revenue (TTM) | €292.77m |
Is PHARM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHARM income statement (TTM) | |
|---|---|
| Revenue | US$339.84m |
| Cost of Revenue | US$36.33m |
| Gross Profit | US$303.51m |
| Other Expenses | US$311.71m |
| Earnings | -US$8.20m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 06, 2025
| Earnings per share (EPS) | -0.012 |
| Gross Margin | 89.31% |
| Net Profit Margin | -2.41% |
| Debt/Equity Ratio | 40.2% |
How did PHARM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/14 06:01 |
| End of Day Share Price | 2025/10/14 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pharming Group N.V. is covered by 11 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Savin | Edison Investment Research |
| Simon Scholes | First Berlin Equity Research GmbH |
| Joseph Pantginis | H.C. Wainwright & Co. |